MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Drug: gemcitabine prolonged continuous infusion
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase II Study of Chemotherapy With Gemcitabine in Prolonged Infusion or With Schedules With Cisplatin in Non-small Cell Lung Cancer Elderly Patients|
- Activity and toxicity of monochemotherapy with gemcitabine as prolonged infusion
- Toxicity and activity of 2 standard polychemotherapy cisplatin based treatments (cisplatin and vinorelbine , and cisplatin and gemcitabine
- patient quality of life
- the prognostic significance of the ADL and IADL scales for time to progression and survival
- exploratory predictive clinical variables for chemotherapy related toxicity
- exploratory predictive clinical variables for response to chemotherapy
|Study Start Date:||June 2002|
|Study Completion Date:||April 2007|
|Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
The study design includes three parallel phase II studies, all with the same rules for patient selection and outcome assessment. In the two studies of cisplatin-based doublets, a dose-finding phase is planned, with subsequent cohorts of 6 patients treated with increasing doses of cisplatin (50-60-70 mg/m²). Following this phase, patients will be assigned to the three studies through a randomization procedure, to reduce selection biases.
Arm A: gemcitabine:
Gemcitabine 1200 mg/m2 intravenously in 2 hours (10 mg/m²/minute) on days 1 & 8 of each cycle, every 21 days, for a maximum of 6 cycles.
Arm B: cisplatin + vinorelbine:
Vinorelbine 25 mg/m² on days 1 & 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1 of each cycle, every 21 days, for a maximum of 6 cycles.
Arm C: cisplatin + gemcitabine:
Gemcitabine 1000 mg/m2,, on days 1 & 8, followed by Cisplatin (50 or 60 or 70 mg/m²) on day 1 of each cycle, every 21 days, for a maximum of 6 cycles.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00401492
|Principal Investigator:||Cesare Gridelli, M.D.||San Giuseppe Moscati Hospital|
|Principal Investigator:||Francesco Perrone, M.D.||National Cancer Institute, Naples Italy|